This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Infinity Expands Executive Leadership Team, Appointing David A. Roth As Senior Vice President, Clinical Development And Medical Affairs

Stocks in this article: INFI

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the appointment of David A. Roth, M.D., as senior vice president, clinical development and medical affairs. In this newly created role, Dr. Roth will have responsibility for the clinical development organization and clinical operations, and he will also build and oversee the medical affairs function. Dr. Roth will serve as a member of Infinity’s executive leadership team and will report to Pedro Santabarbara, M.D., Ph.D., the company’s chief medical officer. Dr. Roth brings to Infinity over 20 years of experience in hematology and oncology research and development.

“It’s a pleasure to welcome David to Infinity. He holds a distinguished track record spanning both industry and academia. His appointment substantially enhances the depth and breadth of Infinity’s hematology and oncology expertise as we rapidly advance our lead program, IPI-145, toward late-stage development and potential registration,” stated Dr. Santabarbara. “David’s experience encompasses both early-stage and registration-phase programs, and the Infinity team looks forward to his contributions as we work to advance and expand our pipeline.”

“Infinity’s PI3K-delta,gamma inhibitor, IPI-145, has the potential to help transform the treatment landscape for patients with hematologic malignancies, and I am pleased to join Infinity at such an exciting time,” commented Dr. Roth. “Infinity has a history grounded in science and academic collaborations, and I’m delighted to be a part of this team as we strive to bring important new treatment options to patients and their physicians.”

Dr. Roth joins Infinity following more than ten years with Pfizer Inc. and Wyeth Pharmaceuticals. At Pfizer, he most recently served as a vice president in Pfizer’s oncology business unit. Dr. Roth joined Pfizer from Wyeth, where he held the role of assistant vice president, clinical research & development and global therapeutic area director of hematology. While at Pfizer and Wyeth, Dr. Roth contributed to the successful regulatory approval of several products, including Bosulif ® (bosutinib), a dual Src/Abl tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia, Xyntha ® and ReFacto AF ® for the treatment of hemophilia A, and BeneFIX ® for the treatment of hemophilia B. Dr. Roth also led the early development of palbociclib, a CDK 4/6 inhibitor, to Phase 3 evaluation in women with ER positive advanced breast cancer. During his tenure at Pfizer and Wyeth, Dr. Roth also co-chaired Pfizer’s oncology research and development board and served on several oncology and hematology R&D leadership teams and governance committees.

In addition to his extensive industry experience, Dr. Roth is an accomplished academic researcher and clinical practitioner. He received his B.S. from the Massachusetts Institute of Technology and his M.D. from Harvard Medical School in the Harvard-M.I.T. Division of Health Sciences and Technology where he remains on the Affiliated Faculty.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs